|
Audiometry findings, present regimen and length of aminoglycoside use in all four patients using capreomycin (Group III) |
|||||||||
| Sr. No. |
Length of treatment (Days) |
Present regimen (Drugs) |
PTA0 |
PTA2 |
PTA4 |
PTA6 |
PTA8 |
PTA10 |
PTAc |
|
|
|||||||||
| 1 |
247 |
C, F, E, P, Clo |
N |
N |
N |
N |
N |
N |
N |
| 2 |
254 |
C, F, E, P, Clo |
N |
N |
N |
N |
N |
N |
N |
| 3* |
120 |
C, F, E, P, Clo |
N |
N |
HFL |
HFL |
HFL |
HFL |
HFL |
| 4 |
240 |
C, F, E, P, Clo |
N |
N |
N |
N |
N |
N |
N |
|
C = capreomycin, F = flouroquinolone, E = ethionamide, P = Paraminosalicylic acid, Clo = Clofazimine, Days = days of aminoglycoside use in present regimen, PTA0 = baseline pure tone audiogram, PTA2 = pure tone audiogram after 2 months of aminoglycoside use, PTA4 = pure tone audiogram after 4 months of aminoglycoside use, PTA6 = pure tone audiogram after 6 months of aminoglycoside use, PTA8 = pure tone audiogram after 8 months of aminoglycoside use, PTA10 = pure tone audiogram after 10 months of aminoglycoside use, PTAc = pure tone audiogram after completion of therapy for MDR-TB, N = Normal, HFL = High frequency loss (hearing loss involving frequencies of 4000, 6000 and 8000 Hz), FLAT = Hearing loss involving frequencies in range of 250–3000 Hz along with involvement of 4000, 6000 and 8000 Hz (Criteria for hearing loss as defined in methods section). * Patient in group III with audiological evidence of hearing loss | |||||||||
Duggal and Sarkar BMC Ear, Nose and Throat Disorders 2007 7:5 doi:10.1186/1472-6815-7-5 |
|||||||||